Literature DB >> 30628751

Predicting progression to type 1 diabetes from ages 3 to 6 in islet autoantibody positive TEDDY children.

Laura M Jacobsen1, Helena E Larsson2, Roy N Tamura3, Kendra Vehik3, Joanna Clasen3, Jay Sosenko4, William A Hagopian5, Jin-Xiong She6, Andrea K Steck7, Marian Rewers7, Olli Simell8, Jorma Toppari8,9, Riitta Veijola10, Anette G Ziegler11, Jeffrey P Krischer3, Beena Akolkar12, Michael J Haller1.   

Abstract

OBJECTIVE: The capacity to precisely predict progression to type 1 diabetes (T1D) in young children over a short time span is an unmet need. We sought to develop a risk algorithm to predict progression in children with high-risk human leukocyte antigen (HLA) genes followed in The Environmental Determinants of Diabetes in the Young (TEDDY) study.
METHODS: Logistic regression and 4-fold cross-validation examined 38 candidate predictors of risk from clinical, immunologic, metabolic, and genetic data. TEDDY subjects with at least one persistent, confirmed autoantibody at age 3 were analyzed with progression to T1D by age 6 serving as the primary endpoint. The logistic regression prediction model was compared to two non-statistical predictors, multiple autoantibody status, and presence of insulinoma-associated-2 autoantibodies (IA-2A).
RESULTS: A total of 363 subjects had at least one autoantibody at age 3. Twenty-one percent of subjects developed T1D by age 6. Logistic regression modeling identified 5 significant predictors - IA-2A status, hemoglobin A1c, body mass index Z-score, single-nucleotide polymorphism rs12708716_G, and a combination marker of autoantibody number plus fasting insulin level. The logistic model yielded a receiver operating characteristic area under the curve (AUC) of 0.80, higher than the two other predictors; however, the differences in AUC, sensitivity, and specificity were small across models.
CONCLUSIONS: This study highlights the application of precision medicine techniques to predict progression to diabetes over a 3-year window in TEDDY subjects. This multifaceted model provides preliminary improvement in prediction over simpler prediction tools. Additional tools are needed to maximize the predictive value of these approaches.
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  autoantibodies; metabolic; pediatric; prediction; type 1 diabetes

Mesh:

Substances:

Year:  2019        PMID: 30628751      PMCID: PMC6456374          DOI: 10.1111/pedi.12812

Source DB:  PubMed          Journal:  Pediatr Diabetes        ISSN: 1399-543X            Impact factor:   3.409


  24 in total

1.  Early determinants of type 1 diabetes: experience from the BABYDIAB and BABYDIET studies.

Authors:  Sandra Hummel; Anette G Ziegler
Journal:  Am J Clin Nutr       Date:  2011-06-01       Impact factor: 7.045

2.  IA-2 autoantibodies predict impending type I diabetes in siblings of patients.

Authors:  K Decochez; I H De Leeuw; B Keymeulen; C Mathieu; R Rottiers; I Weets; E Vandemeulebroucke; I Truyen; L Kaufman; F C Schuit; D G Pipeleers; F K Gorus
Journal:  Diabetologia       Date:  2002-11-12       Impact factor: 10.122

3.  Predicting type 1 diabetes using biomarkers.

Authors:  Ezio Bonifacio
Journal:  Diabetes Care       Date:  2015-06       Impact factor: 19.112

4.  Normal but increasing hemoglobin A1c levels predict progression from islet autoimmunity to overt type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY).

Authors:  Lars C Stene; Katherine Barriga; Michelle Hoffman; Jaime Kean; Georgeanna Klingensmith; Jill M Norris; Henry A Erlich; George S Eisenbarth; Marian Rewers
Journal:  Pediatr Diabetes       Date:  2006-10       Impact factor: 4.866

Review 5.  Prediction and prevention of type 1 diabetes: update on success of prediction and struggles at prevention.

Authors:  Aaron Michels; Li Zhang; Anmar Khadra; Jake A Kushner; Maria J Redondo; Massimo Pietropaolo
Journal:  Pediatr Diabetes       Date:  2015-07-23       Impact factor: 4.866

6.  A risk score for type 1 diabetes derived from autoantibody-positive participants in the diabetes prevention trial-type 1.

Authors:  Jay M Sosenko; Jeffrey P Krischer; Jerry P Palmer; Jeffrey Mahon; Catherine Cowie; Carla J Greenbaum; David Cuthbertson; John M Lachin; Jay S Skyler
Journal:  Diabetes Care       Date:  2007-11-13       Impact factor: 19.112

7.  Natural history of beta-cell autoimmunity in young children with increased genetic susceptibility to type 1 diabetes recruited from the general population.

Authors:  T Kimpimäki; P Kulmala; K Savola; A Kupila; S Korhonen; T Simell; J Ilonen; O Simell; M Knip
Journal:  J Clin Endocrinol Metab       Date:  2002-10       Impact factor: 5.958

8.  Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1.

Authors:  Tihamer Orban; Jay M Sosenko; David Cuthbertson; Jeffrey P Krischer; Jay S Skyler; Richard Jackson; Liping Yu; Jerry P Palmer; Desmond Schatz; George Eisenbarth
Journal:  Diabetes Care       Date:  2009-09-09       Impact factor: 17.152

9.  Role of Type 1 Diabetes-Associated SNPs on Risk of Autoantibody Positivity in the TEDDY Study.

Authors:  Carina Törn; David Hadley; Hye-Seung Lee; William Hagopian; Åke Lernmark; Olli Simell; Marian Rewers; Anette Ziegler; Desmond Schatz; Beena Akolkar; Suna Onengut-Gumuscu; Wei-Min Chen; Jorma Toppari; Juha Mykkänen; Jorma Ilonen; Stephen S Rich; Jin-Xiong She; Andrea K Steck; Jeffrey Krischer
Journal:  Diabetes       Date:  2014-11-24       Impact factor: 9.337

10.  Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for improving the accuracy of the risk classification of type 1 diabetes.

Authors:  Jay M Sosenko; Jay S Skyler; Jeffrey Mahon; Jeffrey P Krischer; Carla J Greenbaum; Lisa E Rafkin; Craig A Beam; David C Boulware; Della Matheson; David Cuthbertson; Kevan C Herold; George Eisenbarth; Jerry P Palmer
Journal:  Diabetes Care       Date:  2014-02-18       Impact factor: 19.112

View more
  11 in total

Review 1.  Clinical and Laboratory Aspects of Insulin Autoantibody-Mediated Glycaemic Dysregulation and Hyperinsulinaemic Hypoglycaemia: Insulin Autoimmune Syndrome and Exogenous Insulin Antibody Syndrome.

Authors:  Tony Huynh
Journal:  Clin Biochem Rev       Date:  2020-12

2.  Index60 Is Superior to HbA1c for Identifying Individuals at High Risk for Type 1 Diabetes.

Authors:  Laura M Jacobsen; Brian N Bundy; Heba M Ismail; Mark Clements; Megan Warnock; Susan Geyer; Desmond A Schatz; Jay M Sosenko
Journal:  J Clin Endocrinol Metab       Date:  2022-09-28       Impact factor: 6.134

3.  HOMA2-B enhances assessment of type 1 diabetes risk among TrialNet Pathway to Prevention participants.

Authors:  Jamie L Felton; David Cuthbertson; Megan Warnock; Kuldeep Lohano; Farah Meah; John M Wentworth; Jay Sosenko; Carmella Evans-Molina
Journal:  Diabetologia       Date:  2021-10-12       Impact factor: 10.460

4.  Yield of a Public Health Screening of Children for Islet Autoantibodies in Bavaria, Germany.

Authors:  Anette-Gabriele Ziegler; Kerstin Kick; Ezio Bonifacio; Florian Haupt; Markus Hippich; Desiree Dunstheimer; Martin Lang; Otto Laub; Katharina Warncke; Karin Lange; Robin Assfalg; Manja Jolink; Christiane Winkler; Peter Achenbach
Journal:  JAMA       Date:  2020-01-28       Impact factor: 56.272

5.  Residual β-cell function after 10 years of autoimmune type 1 diabetes: prevalence, possible determinants, and implications for metabolism.

Authors:  Jin Cheng; Min Yin; Xiaohan Tang; Xiang Yan; Yuting Xie; Binbin He; Xia Li; Zhiguang Zhou
Journal:  Ann Transl Med       Date:  2021-04

6.  Maternal food consumption during late pregnancy and offspring risk of islet autoimmunity and type 1 diabetes.

Authors:  Randi K Johnson; Roy Tamura; Nicole Frank; Ulla Uusitalo; Jimin Yang; Sari Niinistö; Carin Andrén Aronsson; Anette-G Ziegler; William Hagopian; Marian Rewers; Jorma Toppari; Beena Akolkar; Jeffrey Krischer; Suvi M Virtanen; Jill M Norris
Journal:  Diabetologia       Date:  2021-03-30       Impact factor: 10.460

7.  Beta cell function in participants with single or multiple islet autoantibodies at baseline in the TEDDY Family Prevention Study: TEFA.

Authors:  Maria Månsson Martinez; Falastin Salami; Helena Elding Larsson; Jorma Toppari; Åke Lernmark; Jukka Kero; Riitta Veijola; Jaakko J Koskenniemi; Päivi Tossavainen; Markus Lundgren; Henrik Borg; Anastasia Katsarou; Marlena Maziarz; Carina Törn
Journal:  Endocrinol Diabetes Metab       Date:  2020-11-05

8.  Use of insulin pump therapy is associated with reduced hospital-days in the long-term: a real-world study of 48,756 pediatric patients with type 1 diabetes.

Authors:  Marie Auzanneau; Beate Karges; Andreas Neu; Thomas Kapellen; Stefan A Wudy; Corinna Grasemann; Gabriele Krauch; Eva Maria Gerstl; Gerhard Däublin; Reinhard W Holl
Journal:  Eur J Pediatr       Date:  2020-12-01       Impact factor: 3.183

9.  Prediction of the development of islet autoantibodies through integration of environmental, genetic, and metabolic markers.

Authors:  Bobbie-Jo M Webb-Robertson; Lisa M Bramer; Bryan A Stanfill; Sarah M Reehl; Ernesto S Nakayasu; Thomas O Metz; Brigitte I Frohnert; Jill M Norris; Randi K Johnson; Stephen S Rich; Marian J Rewers
Journal:  J Diabetes       Date:  2020-08-16       Impact factor: 4.006

10.  Simplifying prediction of disease progression in pre-symptomatic type 1 diabetes using a single blood sample.

Authors:  Naiara G Bediaga; Connie S N Li-Wai-Suen; Michael J Haller; Stephen E Gitelman; Carmella Evans-Molina; Peter A Gottlieb; Markus Hippich; Anette-Gabriele Ziegler; Ake Lernmark; Linda A DiMeglio; Diane K Wherrett; Peter G Colman; Leonard C Harrison; John M Wentworth
Journal:  Diabetologia       Date:  2021-08-02       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.